Compare MASS & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MASS | PRTC |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | 90 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 386.7M |
| IPO Year | 2020 | N/A |
| Metric | MASS | PRTC |
|---|---|---|
| Price | $6.16 | $16.70 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 408.7K | 4.8K |
| Earning Date | 11-10-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $65,045,000.00 | $6,391,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.54 | N/A |
| P/E Ratio | ★ N/A | $7.94 |
| Revenue Growth | 36.21 | ★ 1265.60 |
| 52 Week Low | $1.81 | $13.30 |
| 52 Week High | $9.34 | $24.99 |
| Indicator | MASS | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 50.35 |
| Support Level | $6.13 | $15.50 |
| Resistance Level | $6.64 | $16.24 |
| Average True Range (ATR) | 0.40 | 0.42 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 58.93 | 54.88 |
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.